Pharmaceuticals, Biotechnology and Life Sciences
Alkermes plcp has announced that the U.S. Food and Drug Administration (FDA) has approved Aristadatm (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
The U.S. Food and Drug Administration ordered on Monday the three manufacturers of duodenoscopes marketed in the U.S. to conduct postmarket surveillance studies to better understand how the devices are reprocessed in real-world settings.
Johnson & Johnson has completed the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion.
The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology or Medicine with one half jointly to William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites and the other half to Youyou Tu for her discoveries concerning a novel therapy against Malaria.
William C. Campbell and Satoshi Ōmura split Nobel prize in Physiology or Medicine 2015 with Youyou Tu, for discoveries regarding novel therapies for some of the most devastating parasitic diseases.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
Roche’s new HbA1c testing solution, the cobas c 513 analyser, is now available for countries accepting the CE mark,
Cell Therapy Ltd will begin the application process for a conditional marketing authorisation (CMA) for Heartcel, the first allogeneic stem cell therapy to regenerate the human heart, in Europe.
Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, intends to join the AIM market of the London Stock Exchange by way of a Placing to raise approximately £5 million.
FDA allows Avita to expand its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.